Protocol No.: S1905

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)
Principal Investigator
Veltri, Lauren
Phase
I/II (Cancer Control)
Age Group
Adult
Applicable Disease Site
Leukemia
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov